News & Media
10 Million Vaccine Doses Administered, 5.5 Million Michiganders Vaccinated
More than 10 million primary series doses of the safe and effective COVID-19 vaccine have been administered to Michiganders. The state has also administered more than 207,000 third doses to those who are immunocompromised and booster doses to eligible individuals. To date, 68.3% of Michiganders age 16 years or older have gotten at least their first dose of one of the three safe, effective vaccines – bringing the state close to its goal of 70% vaccination rate.
From January to July 2021, unvaccinated Michiganders accounted for 98% of COVID cases, 95% of hospitalizations and 96% of deaths.
Total vaccines doses, including primary series and additional or booster doses:
- 5,967,776 doses of Pfizer
- 3,900,419 doses of Moderna
- 352,317 doses of Johnson & Johnson
Michiganders ages 12 and older are eligible to be vaccinated against COVID-19.
In addition, CDC recommends the following groups should receive a booster shot of Pfizer-BioNTech’s COVID-19 vaccine at least six months after their Pfizer-BioNTech primary series:
- People 65 years and older and residents aged 18 and older in long-term care settings.
- People aged 50 through 64 with certain underlying medical conditions.
CDC recommends the following groups may receive a booster shot of Pfizer-BioNTech’s COVID-19 vaccine at least six months after their Pfizer-BioNTech primary series based on their individual benefits and risks:
- People aged 18 through 49 who are at high risk for severe COVID-19 due to certain underlying medical conditions.
- People aged 18 through 64 years who are at increased risk for COVID-19 exposure and transmission because of occupational or institutional setting.
Additionally, Michiganders with moderately to severely compromised immune systems should receive an additional dose of mRNA COVID-19 vaccine at least 28 days after a second dose of Pfizer-BioNTech COVID-19 or Moderna COVID-19 vaccine. This additional dose is intended to improve the response of people who are immunocompromised to their initial vaccine series.